Advertisement

 

 

High Level Expression and Purification of the Clinically Active Antimicrobial Peptide P-113 in Escherichia coli.

High Level Expression and Purification of the Clinically Active Antimicrobial Peptide P-113 in Escherichia coli.
Author Information (click to view)

Cheng KT, Wu CL, Yip BS, Yu HY, Cheng HT, Chih YH, Cheng JW,


Cheng KT, Wu CL, Yip BS, Yu HY, Cheng HT, Chih YH, Cheng JW, (click to view)

Cheng KT, Wu CL, Yip BS, Yu HY, Cheng HT, Chih YH, Cheng JW,

Advertisement

Molecules (Basel, Switzerland) 2018 03 3023(4) pii 10.3390/molecules23040800

Abstract

P-113, which was originally derived from the human saliva protein histatin 5, is a histidine-rich antimicrobial peptide with the sequence AKRHHGYKRKFH. P-113 is currently undergoing phase II clinical trial as a pharmaceutical agent to fight against fungal infections in HIV patients with oral candidiasis. Previously, we developed a new procedure for the high-yield expression and purification of hG31P, an analogue and antagonist of human CXCL8. Moreover, we have successfully removed lipopolysaccharide (LPS, endotoxin) associated with hG31P in the expression with. In this paper, we have used hG31P as a novel fusion protein for the expression and purification of P-113. The purity of the expressed P-113 is more than 95% and the yield is 4 mg P-113 per liter ofcell culture in Luria-Bertani (LB) medium. The antimicrobial activity of the purified P-113 was tested. Furthermore, we used circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy to study the structural properties of P-113. Our results indicate that using hG31P as a fusion protein to obtain large quantities of P-113 is feasible and is easy to scale up for commercial production. An effective way of producing enough P-113 for future clinical studies is evident in this study.

Submit a Comment

Your email address will not be published. Required fields are marked *

17 − 12 =

[ HIDE/SHOW ]